2 news items
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
TAK
9 May 24
, offset by a decrease in Neuroscience.
GI revenue
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
TAK
9 May 24
for approximately 50% of our total revenue and helping to offset remaining impact from generic competition. With no further significant loss
- Prev
- 1
- Next